US SEC Filing Intelligence

New Federal Contractors — March 01, 2026

A single massive $20.65B cost-plus award fee contract for Lockheed Martin Services to manage DOE's Y-12 plant through 2027 dominates this period, signaling exceptional long-term revenue stability in government-owned facilities operations. Zero outlays despite the 43-year history highlight execution risks amid DOE budget dependence. Investors should prioritize Lockheed Martin for defense-industrial exposure while monitoring funding triggers.

Significant Contract Modifications ($10M+) — March 01, 2026

Lockheed Martin's $20.65B cost-plus contract for Y-12 plant management through 2027 delivers unmatched revenue visibility in DOE facilities operations. The fully funded structure (minimal gap between obligation and base+options) signals high stability for aerospace & defense. Zero outlays despite 43-year history flags execution risks tied to DOE budgets, prioritizing funding monitoring.

Contract Deobligations Alert — March 01, 2026

A single massive $20.65B long-term DOE contract for Lockheed Martin Services underscores exceptional revenue visibility through 2027 in Y-12 nuclear facilities management, signaling bullish stability for Lockheed Martin Corp amid full and open competition. Zero outlays to date highlight execution risks but minimal obligation gaps suggest fully funded potential. Investors should prioritize monitoring DOE budgets for reimbursements and follow-on opportunities in GOCO operations.

Contract Option Exercises — March 01, 2026

Lockheed Martin Services secures a $20.65B cost-plus award fee contract with DOE for Y-12 plant management through Feb 2027, signaling strong revenue visibility in government-owned contractor-operated (GOCO) facilities. Despite zero outlays to date, the fully funded structure and full competition award highlight stability in facilities support services. Investors should monitor DOE budgets for execution risks amid this outsized single-contract concentration.

All DOE Contracts — March 01, 2026

A single $20.65B DOE contract for Lockheed Martin underscores exceptional long-term revenue stability in Y-12 plant management through 2027, providing high-confidence bullish signal for the company amid full and open competition. No outlays despite 43-year history flags execution risks tied to DOE budgets, warranting caution on near-term cash flows. Fully funded structure and follow-on potential position Lockheed as a prime watch item in facilities support services.

Mega Contracts Monitor ($100M+) — March 01, 2026

A single $20.65B mega-contract to Lockheed Martin Services for Y-12 plant management through 2027 delivers unmatched revenue visibility via cost-plus structure in DOE GOCO operations. Full and open competition win reinforces Lockheed's entrenched position in facilities support (NAICS 561210). Zero outlays flag execution risks, but fully funded profile signals long-term stability for defense contractors.

High-Value Federal Grants ($5M+) — March 01, 2026

A single massive $20.65B cost-plus contract awarded to Lockheed Martin Services, LLC for Y-12 plant management through Feb 2027 signals strong revenue visibility in DOE facilities operations. Despite zero outlays to date, the fully funded structure and full/open competition award underscore long-term stability for Lockheed Martin in NAICS 561210 services. Investors should monitor DOE budget execution amid funding risks, with potential follow-on opportunities post-2027.

DOE Energy Grants — March 01, 2026

A single massive $20.65B DOE contract awarded to Lockheed Martin Services underscores long-term revenue stability for Y-12 plant management through Feb 2027, signaling bullish commitment to GOCO facilities operations amid full competition. No outlays despite 2026 period highlight execution risks tied to DOE budgeting. Investors should prioritize Lockheed Martin for defense/energy services exposure with potential follow-on beyond 2027.

General Federal Contracts — March 01, 2026

A single massive $20.65B cost-plus contract awarded to Lockheed Martin Services underscores exceptional long-term revenue visibility for Lockheed Martin Corp in DOE Y-12 operations through 2027. Despite zero outlays to date, the fully funded structure signals stability in facilities support services. Investors should monitor DOE funding for execution risks amid budget dependencies.

NME Blockbuster Approvals — February 28, 2026

FDA approval of LOARGYS (PEGZILARGINASE-NBLN) on Feb 23, 2026, delivers a bullish catalyst for Immedica Pharma AB via original NME with Priority Review and Orphan Drug status, enabling premium pricing and exclusivity. This isolated event in the NME Blockbuster stream signals strong regulatory momentum but lacks indication details for market sizing. Investors should prioritize monitoring commercial launch for revenue potential amid unknown competition.

Biotech Small-Cap Approvals — February 28, 2026

This one-day period saw 12 neutral generic ANDA approvals out of 13 records, concentrated in Brivaracetam (4 sponsors), Liraglutide (2), and Sitagliptin Phosphate (2), signaling broad generic portfolio expansions for small-cap sponsors but routine pricing pressure ahead. The sole bullish outlier is Immedica Pharma AB's priority-reviewed NME Orphan Drug BLA for LOARGYS (PEGZILARGINASE-NBLN), offering premium positioning via exclusivity. Investors should prioritize Immedica for growth while monitoring generic erosion in epilepsy and diabetes segments.

13 total filings

Big Pharma Approvals — February 28, 2026

FDA supplemental approval of Regeneron's DUPIXENT under Priority Review signals bullish label expansion potential, accelerating market access for this blockbuster. Lack of disclosed indication details tempers full market impact assessment. Investors should monitor for therapeutic specifics to gauge revenue upside amid pricing risks.

Orphan Drug Approvals — February 28, 2026

Immedica Pharma AB's FDA approval of LOARGYS (PEGZILARGINASE-NBLN) via priority review for an original NME orphan drug represents the period's sole bullish catalyst, enabling near-term commercial launch with exclusivity and premium pricing. Two identical neutral signals for Array Biopharma's Encorafenib highlight data redundancy and lack of material developments, signaling portfolio stability but no upside. Overall, sparse activity underscores selective orphan drug opportunities amid neutral biotech backdrop.

3 total filings

New Drug Approvals (Original) — February 28, 2026

This one-day period (approvals Feb 23-24, 2026) features 12 routine ANDA generic approvals, mostly from Indian sponsors, concentrated in Brivaracetam (4 approvals), Liraglutide/Sitagliptin Phosphate (2 each), signaling imminent pricing erosion in these molecules. The standout event is Immedica Pharma AB's priority-reviewed Orphan NME BLA approval for PEGZILARGINASE-NBLN, a rare bullish catalyst amid generic dominance. Neutral implications dominate, with no bearish signals but elevated competitive risks for crowded generics.

13 total filings

Defense Manufacturing Contracts — February 28, 2026

Two major defense manufacturing contracts totaling $1.57B in obligations signal bullish backlog growth for Austal USA (Austal Limited) and Lockheed Martin, with combined potential value exceeding $3.7B via options. Long-duration commitments (to 2030 and 2033) provide revenue visibility amid execution risks from low outlays ($61M for Austal, 64% for Lockheed) and cost structures. Investors should prioritize monitoring option exercises for uplift in shipbuilding and space sectors.

2 total filings

DHS Homeland Security Contracts — February 28, 2026

DHS contracts for Feb 28, 2026, total $1.47B, dominated by Austal USA's $1.23B Coast Guard OPC shipbuilding award (84% of value, options to $3.3B), signaling robust fleet modernization demand. Granite's $169M CBP border barrier contract adds infrastructure momentum, while DDL Omni's $72M legacy engineering deal remains neutral with $0 outlay post-2022 end. Aggregate low outlays (4% of obligations) highlight multi-year revenue potential offset by execution risks in fixed-price structures.

3 total filings

VA Healthcare & Services Contracts — February 28, 2026

Two high-value VA contracts totaling $328.6M awarded to diverse-owned firms (veteran and minority) via full/open competition signal strong demand for medical disability exams and IT enterprise testing, both rated bullish for revenue potential. VES shows near-complete cash realization ($164M outlayed of $166M), while PSI offers multi-year upside to 2025 ($162M obligation, $164M base+options). Investors should prioritize VA services exposure amid robust funding utilization patterns.

2 total filings

NASA & Space Contracts Intelligence — February 28, 2026

Lockheed Martin secured a $347.8M NASA contract (potential $396.5M with options) for the Lucy mission to Jupiter's Trojan asteroids, spanning 2017-2033, delivering long-term revenue visibility in space vehicle manufacturing. This bullish signal underscores NASA's sustained deep-space exploration funding amid a single-contract period. Investors should monitor execution risks over the extended timeline and option exercises for full value realization.